ArticleRheumatology international2021
Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study.
Article in Rheumatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Juvenile Systemic Sclerosis in a Single Center: Clinical Features, Capillaroscopic Findings, Immunological Profile, and Treatment Outcomes-A Retrospective Descriptive Analysis.Children (Basel, Switzerland) · 2026Article
- Clinical characteristics, autoantibody profiles, and therapeutic outcomes of juvenile systemic sclerosis: an 11-year single-center experience from China.Frontiers in immunology · 2026Article
- Progress of biological agents and CAR cell therapy in the treatment of common autoimmune diseases in children.Frontiers in pediatrics · 2026Review
- Coexistence of Localized and Systemic Juvenile Scleroderma: A Case Report and Review of Literature.Clinical case reports · 2025Article
- Application of the Scleroderma Clinical Trials Consortium Damage Index in patients with juvenile systemic sclerosis.Pediatric rheumatology online journal · 2025Article
- New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Esophageal motility in systemic sclerosis before and after autologous hematopoietic cell transplantation.Clinical rheumatology · 2023Article
- Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?Biomedicines · 2022Review
- Problems to Consider Before Determining the Regimen of the Treatment for Juvenile Systemic Sclerosis Treatment: A Case Report Where Tocilizumab Monotherapy Succeeded Efficiently and Safely.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2022Article
- Screening and identification of potential biomarkers and therapeutic targets for systemic sclerosis-associated interstitial lung disease.Archives of rheumatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the efficacy and safety of anti-interleukin (IL)-6 receptor antibody tocilizumab (TCZ) as a treatment option of juvenile systemic sclerosis (JSS). Nine JSS patients were assigned to a TCZ, additionally to conventional treatment (steroids, methotrexate, mycophenolate-mofetil). The modified Rodnan skin score (mRSS), carbon-monoxide diffusion capacity (DLCO), thorax high-resolution tomography (HRCT), patient global assessment (PGA) and Juvenile Systemic Sclerosis Severity (J4S) score were used to explore the efficacy of treatment. Nine JSS patients were treated with TCZ with a median treatment duration of 10 (1-21) months. Nine patients (77.8%) had radiologically confirmed improvement on thorax HRCT, 7 (77.8%) had decreased PGA (mean pre-treatment PGA 3.7 vs. 2.3 post-treatment PGA 2), 6 (66.7%) had increased DLCO (mean pre-treatment DLCO 69.14% vs. post-treatment DLCO 79.50%) after the TCZ treatment. In all patients mRSS and the J4S decreased: 26.1 vs. 19.7 and 8.2 vs. 4.7, respectively. Changes in mRSS, DLCO, PGA and J4S were statistically significant: p = 0.012, 0.04, 0.026 and 0.007, respectively. All patients tolerated well TCZ treatment. JSS is a rare condition characterized with skin fibrosis and internal organ involvement. Tocilizumab represents a potential treatment option for patients unresponsive to conventional treatment. Long-term prospective studies with higher number of patients are needed to provide more relevant data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.